leukemia

Novartis Immunocellular Therapy Approved by FDA

Novartis Immunocellular Therapy Approved by FDA

Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..